Peptides for Disease Research

We’re rapidly producing custom peptides and peptide libraries for the major proteins of SARS-COV-2. With high quality products available fast for researchers combating Covid19, come and see Mimotopes for all of your peptide needs.

Custom Peptide Libraries

The advantage of our proprietary parallel synthesis technology is that Mimotopes can synthesise hundreds of peptides simultaneously, and thus greatly reduce the price and time to delivery.

High quality Peptide Libraries affordable prices

30 Years Experience

Mimotopes is the founder of peptide library technology. We have only continued to grow and learn over the decades – now our expertise is unrivaled.

We work tirelessly to stay ahead of the game to ensure, as always, that we supply the best possible products, including SARS-CoV-2 peptides.

Efficient & Economical Screening Solutions

PepsetTM PeptideLibraries have dozens of potential applications. With applications in covid19 vaccine and drug development, disease screening, and epitope mapping, a peptide library can be exclusively designed to your specifications, for your research. 

  • Discover crucial residues with an Alanine Scan Library
  • Map epitopes with an Overlapping Library
  • Narrow down the shortest active sequences with a Truncated Library

Dozens of Options to Customise

A standard PepSetTM Peptide Library can be supplied as with a precise length and offset designed to best suit your assays, but that’s not all. Modifications and labels can be applied to the termini or even within the sequence. Arrange a consultation to discuss your options and design your library.

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

✉ australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

✉ useast@mimotopes.com
     uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com


UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

  ✉ useast@mimotopes.com 
  ✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com

UK/ Europe/ Africa/ Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Go to article: Home | An (in)active pill problemGo to article: EditorialGo to article: SHL Group Company InsightGo to article: Scandinavian HealthGo to article: ContentsGo to article: NSFGo to article: NewsGo to article: AlmacGo to article: Covid-19 executive briefing by GlobalDataGo to article: Gerteis Company InsightGo to article: GerteisGo to article: Digital biomarkers are emerging as important predictive tools to support the gloGo to article: Accurate Biometrics Company Insight Go to article: Accurate BiometricsGo to article: Almost 70 potential Covid-19 drug and experimental compound candidates identifiedGo to article: Datwyler Company Insight Go to article: DatwylerGo to article: Risk assessment of Covid-19 on patients suffering from IBDGo to article: Zenatek Go to article: The pharma industry briefingGo to article: FargoGo to article: Another bump in the road for mumps treatmentGo to article: Last TechnologyGo to article: From Covid-19 to SARS: what becomes of the whistleblowers?Go to article: ButterworthGo to article: Peptomyc: the quest for a ‘universal’ cancer treatmentGo to article: Q&A: is pharma ready to address the health effects of climate change?Go to article: Modality SolutionsGo to article: Not-so-inactive ingredients: a sore spot for patients?Go to article: Beyond M&As: will 2020 be the year of the spin-off? Go to article: VEGA Company Insight Go to article: VEGA AustraliaGo to article: Q&A with Genocea: improving cancer treatment with precise, personalised targetsGo to article: MimotopesGo to article: Pharma Playbook: an inside look at Signals Analytics vast therapeutic database Go to article: ILC Dover Go to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue